Gene therapy for rare brain disease sets a new pricing record at $4.25 million
FiercePharma - 20-Mar-2024Its record-breaking price raises questions about affordability and access
Fraiser Kansteiner
Writer at Fierce Pharma
Fraiser Kansteiner is a staff writer at Fierce Pharma. He joined the Fierce team in 2020 and covers topics such as manufacturing, COVID-19 and drug delivery. He also manages Fierce Biotech and Fierce Pharma’s LinkedIn showcase pages. Before diving into pharma reporting, Fraiser worked as a writing teaching fellow and later as a full-time writing teacher in New York City.
Visit website: https://www.fiercepharma.com/person/fraiser-kansteiner-0
See also: 
FiercePharma
- FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company.
Details last updated 08-Apr-2024
Articles written by Fraiser Kansteiner
